The University of Chicago

University of Pittsburgh

University of Illinois

Cornell University

Instituto Nacional De Enfermedades Respiratorias Ismael Cosio Villegas—d.f.

Imre Noth

Naftali Kaminski

Kevin Gibson

Jose David Herazo-Maya

Joe G N Garcia

Yong Huang

Fernando E Martinez

Thomas J Richards

Ivan Rosas

Kazuhisa Konishi

Moises Selman

Justin Oldham

Bernadette R Gochuico

Fernando Martinez

Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.

Biomarkers for assessing idiopathic pulmonary fibrosis

Aspects of the disclosure relate to a method for treating idiopathic pulmonary fibrosis (IPF) in a patient with N-acetylcysteine (NAC) comprising administering NAC to a patient after a sample from the patient has been genotyped and determined to be any one of: a) homozygous or heterozygous for a thymine at the single nucleotide polymorphism rs3750920; b) homozygous or heterozygous for guanine at the single nucleotide polymorphism rs5743894; or c) homozygous or heterozygous for thymine at the single nucleotide polymorphism rs35705950.

Method for treating idiopathic pulmonary fibrosis

Disclosed are methods are kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.

The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis ('IPF') and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.

Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation

Growing community of inventors

Chicago, IL, United States of America

Imre Noth